Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
YARDLEY, Pa., Nov. 18, 2023 (GLOBE NEWSWIRE) — OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-qualified stock option awards to…